OS (Adenocarcinoma):
Benefit consistent in subgroup analyses
Characteristic
Hazard ratio
(95% CI)
Int.
p value
Overall
0.83 (0.70–0.99)
Sex
0.794
Female
0.84 (0.63–1.12)
Male
0.84 (0.68–1.05)
Age class
0.756
<65 years
0.83 (0.68–1.02)
≥65 years
0.82 (0.58–1.15)
Ethnic origin
0.532
Asian
0.89 (0.61–1.31)
Non-Asian
0.81 (0.67–0.98)
Smoking status
0.511
Current smoker/ex-smoker
0.86 (0.69–1.06)
Never smoker
0.81 (0.60–1.09)
ECOG PS
0.785
0
0.79 (0.57–1.08)
1
0.85 (0.70–1.04)
Brain metastases
0.125
No
0.80 (0.67– 0.96)
Yes
1.27 (0.67–2.38)
Prior bevacizumab
0.241
No
0.85 (0.71–1.01)
Yes
0.61 (0.31–1.20)
Time since start of first-line
0.419
<9 months
0.75 (0.60–0.92)
≥9 months
0.89 (0.66–1.19)
Best response to first-line
0.189
CR/PR/SD
0.90 (0.73–1.10)
PD
0.62 (0.41–0.94)
0.4 0.5
1.0
2.0 2.5
Favours nintedanib
Favours placebo
Reck M,
et al
.
Lancet Oncol
. 2014;15:143-55.
